View Financial HealthAqua Bio Technology 配当と自社株買い配当金 基準チェック /06Aqua Bio Technology現在配当金を支払っていません。主要情報0%配当利回り-2.2%バイバック利回り総株主利回り-2.2%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向0%最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesNew Risk • May 13New major risk - Revenue sizeThe company makes less than US$1m in revenue. Total revenue: kr7.5m (US$822k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 62% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 6x increase in shares outstanding). Revenue is less than US$1m (kr7.5m revenue, or US$822k). Market cap is less than US$10m (kr79.4m market cap, or US$8.67m).お知らせ • Mar 21Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 3.6824 million.Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 3.6824 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 388,240 Price\Range: NOK 5 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 348,240 Price\Range: NOK 5 Transaction Features: Rights Offeringお知らせ • Feb 13Aqua Bio Technology ASA has filed a Follow-on Equity Offering in the amount of NOK 4 million.Aqua Bio Technology ASA has filed a Follow-on Equity Offering in the amount of NOK 4 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 800,000 Price\Range: NOK 5 Transaction Features: Rights Offering分析記事 • Jan 20Cautious Investors Not Rewarding Aqua Bio Technology ASA's (OB:ABTEC) Performance CompletelyYou may think that with a price-to-sales (or "P/S") ratio of 0.6x Aqua Bio Technology ASA ( OB:ABTEC ) is a stock worth...New Risk • Dec 22New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 46% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr18m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 70% per year over the past 5 years. Shareholders have been substantially diluted in the past year (46% increase in shares outstanding). Market cap is less than US$10m (kr77.9m market cap, or US$7.69m).New Risk • Dec 05New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 46% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr18m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 70% per year over the past 5 years. Shareholders have been substantially diluted in the past year (46% increase in shares outstanding). Market cap is less than US$10m (kr79.0m market cap, or US$7.81m).Reported Earnings • Dec 01Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: kr6.88m (down 70% from 3Q 2024). Net loss: kr5.13m (loss narrowed 97% from 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 26 percentage points per year, which is a significant difference in performance.New Risk • Dec 01New minor risk - Financial positionThe company has a high level of debt. Net debt to equity ratio: 1,462% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). High level of non-cash earnings (73% accrual ratio). Revenue is less than US$1m. Market cap is less than US$10m (kr53.3m market cap, or US$5.27m). Minor Risk High level of debt (1,462% net debt to equity).お知らせ • Nov 22Aqua Bio Technology ASA, Annual General Meeting, May 22, 2026Aqua Bio Technology ASA, Annual General Meeting, May 22, 2026.分析記事 • Nov 21Is Aqua Bio Technology (OB:ABTEC) A Risky Investment?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...お知らせ • Nov 21+ 3 more updatesAqua Bio Technology ASA to Report Q3, 2025 Results on Nov 26, 2025Aqua Bio Technology ASA announced that they will report Q3, 2025 results on Nov 26, 2025分析記事 • Sep 24Aqua Bio Technology ASA (OB:ABTEC) Might Not Be As Mispriced As It Looks After Plunging 29%Aqua Bio Technology ASA ( OB:ABTEC ) shareholders that were waiting for something to happen have been dealt a blow with...New Risk • Aug 31New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr32m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr32m free cash flow). Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings have declined by 73% per year over the past 5 years. Shareholders have been substantially diluted in the past year (57% increase in shares outstanding). Market cap is less than US$10m (kr85.9m market cap, or US$8.54m).分析記事 • Aug 05Positive Sentiment Still Eludes Aqua Bio Technology ASA (OB:ABTEC) Following 27% Share Price SlumpOB:ABTEC 1 Year Share Price vs Fair Value Explore Aqua Bio Technology's Fair Values from the Community and select yours...分析記事 • Jun 21Aqua Bio Technology ASA (OB:ABTEC) Stock's 54% Dive Might Signal An Opportunity But It Requires Some ScrutinyThe Aqua Bio Technology ASA ( OB:ABTEC ) share price has softened a substantial 54% over the previous 30 days, handing...お知らせ • May 22Coc Invest AS, Cover Consult AS, Fiala Holding As, Hartmanns Norge As, Kø Consulting AS and Odp Holding As entered into an agreement to acquire 3D Innovation Nordic AS from Aqua Bio Technology ASA (OB:ABTEC).Coc Invest AS, Cover Consult AS, Fiala Holding As, Hartmanns Norge As, Kø Consulting AS and Odp Holding As entered into an agreement to acquire 3D Innovation Nordic AS from Aqua Bio Technology ASA (OB:ABTEC) on May 20, 2025. In separate transactions Aqua Bio Technology ASA (ABTEC) has entered into agreements with Coc Invest AS, Odp Holding AS, Fiala Holding AS, Kø Consulting AS, Cover Consult AS, and Hartmanns Norge AS for the sale of Ovalen AS, Cover Brands As. The combined consideration for Ovalen AS, 3D Innovation Nordic AS, and Coverbrands AS will be settled in 11 million Aqua Bio Technology shares and NOK 0.5 million in cash.お知らせ • May 21Coc Invest AS, Odp Holding As, Fiala Holding As, Hartmanns Norge As, Kø Consulting AS and Cover Consult AS entered into an agreement to acquire Cover Brands As from Aqua Bio Technology ASA (OB:ABTEC).Coc Invest AS, Odp Holding As, Fiala Holding As, Hartmanns Norge As, Kø Consulting AS and Cover Consult AS entered into an agreement to acquire Cover Brands As from Aqua Bio Technology ASA (OB:ABTEC) on May 20, 2025. In separate transactions Aqua Bio Technology ASA (ABTEC) has entered into agreements with Coc Invest AS, Odp Holding AS, Fiala Holding AS, Kø Consulting AS, Cover Consult AS, and Hartmanns Norge AS for the sale of Ovalen AS, 3D Innovation Nordic AS. The combined consideration for Ovalen AS, 3D Innovation Nordic AS, and Coverbrands AS will be settled in 11 million Aqua Bio Technology shares and NOK 0.5 million in cash.分析記事 • May 07Aqua Bio Technology ASA (OB:ABTEC) Stock Rockets 40% But Many Are Still Ignoring The CompanyThose holding Aqua Bio Technology ASA ( OB:ABTEC ) shares would be relieved that the share price has rebounded 40% in...お知らせ • Apr 09Aqua Bio Technology Asa Announces Board ChangesAqua Bio Technology ASA at the extraordinary general meeting held on 9 April 2025, Roger Sedal is elected as new Chairman of the Board of Directors. Jan Pettersson shall resign from the Board of Directors. Following this, the Board of Directors shall consist of: Roger Sedal, Chairman; Lena Aas Varming, Director; Sofie Aimee Siem, Director; David Huggins, Director; Terje Blytt, Director; Jon Olav Ødegård, Observer.お知らせ • Apr 04Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 2.055988 million.Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 2.055988 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 4,111,975 Price\Range: NOK 0.5 Transaction Features: Rights Offeringお知らせ • Mar 13Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 24.216 million.Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 24.216 million. Security Name: Shares Security Type: Common Stock Securities Offered: 48,432,000 Price\Range: NOK 0.5 Transaction Features: Subsequent Direct ListingNew Risk • Mar 11New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: kr80.1m (US$7.43m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (31% average weekly change). High level of non-cash earnings (41% accrual ratio). Shareholders have been substantially diluted in the past year (86% increase in shares outstanding). Market cap is less than US$10m (kr80.1m market cap, or US$7.43m).お知らせ • Feb 26+ 2 more updatesAqua Bio Technology ASA, Annual General Meeting, Jun 25, 2025Aqua Bio Technology ASA, Annual General Meeting, Jun 25, 2025.お知らせ • Feb 12Aqua Bio Technology ASA Provides Earnings Guidance for the Fiscal Year 2025Aqua Bio Technology ASA provided earnings guidance for the fiscal year 2025. For the period, consolidated revenue is expected to exceed NOK 500.0 million applying Norwegian Generally Accepted Accounting Principles (N-GAAP), indicating conservative revenue growth compared to pro forma revenue (based on N-GAAP) assuming all 2024 acquisitions were completed as of January 1, 2024.お知らせ • Jan 21Aqua Bio Technology Announces Resignation of Celine Maria Sedal from Board of DirectorsAqua Bio Technology ASA has been informed that Board member Celine Maria Sedal has chosen to resign from the Company's Board of Directors with immediate effect. The resignation is due to Sedal not being able to hold the position as member of the Board of Directors in her newly assumed employment.New Risk • Dec 30New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (22% average weekly change). High level of non-cash earnings (41% accrual ratio). Shareholders have been substantially diluted in the past year (97% increase in shares outstanding). Minor Risk Market cap is less than US$100m (kr234.0m market cap, or US$20.6m).New Risk • Nov 22New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 130% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Shareholders have been substantially diluted in the past year (130% increase in shares outstanding). Minor Risks Revenue is less than US$5m (kr14m revenue, or US$1.2m). Market cap is less than US$100m (kr217.7m market cap, or US$19.6m).New Risk • Nov 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Norwegian stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Shareholders have been diluted in the past year (47% increase in shares outstanding). Revenue is less than US$5m (kr14m revenue, or US$1.2m). Market cap is less than US$100m (kr191.1m market cap, or US$17.3m).お知らせ • Oct 22Aqua Bio Technology ASA Announces CEO Changes, Effective December 1, 2024Aqua Bio Technology ASA announced that Fredrik W. Henriksen has been appointed Chief Executive Officer of the Company. Mr. Henriksen assumes his position on 1 December 2024, and replaces Håvard Lindstrøm, who has served as CEO for more than 3 years. Mr. Henriksen has since 2016 served as Commercial Director in Norengros. He has also 15 years in different start-ups prior to working within the sales and distribution industry. Håvard Lindstrøm started as CEO in 2021.お知らせ • Aug 29Aqua Bio Technology ASA (OB:ABTEC) completed the acquisition of 3d Innovation Nordic As from Coc Invest AS.Aqua Bio Technology ASA (OB:ABTEC) entered into an agreement to acquire 3d Innovation Nordic As from Coc Invest AS on April 25, 2024. Pursuant to the Agreement, Aqua Bio Technology also agreed to acquire Printprofil AS and Check Please AS from Coc Invest AS. The combined consideration for both the transactions is NOK 40.4 million. Under the Agreement, the purchase price for the Acquisitions shall be settled in a combination of shares and cash, subject to certain conditions. NOK 5 million shares in ABT will be issued at a price of NOK 6 per share, with a 3-year lock up. The cash will be total NOK 15 million, divided into two installments, depending on the Target Group's (collectively Printprofil AS and Check Please AS (jointly with 3D Innovation) financial results. The first NOK 5 million is triggered by an EBT of NOK 6 million in the Target Group, the next NOK 10 million when the Target Group achieves an EBT of NOK 10 million. As of 2023, 3d Innovation, Printprofil AS and Check Please had reported a EBIDTA of NOK 5 million and turnover of NOK 87.6 million, of which 3d Innovation had a turnover of NOK 73 million. The completion of the Acquisitions is subject to satisfactory due diligence and approval from ABT's board of directors. Aqua Bio Technology ASA (OB:ABTEC) completed the acquisition of 3d Innovation Nordic As from Coc Invest AS on August 28, 2024. The purchase price for the Transaction shall be settled in a combination of shares and cash, subject to certain conditions. The share component comprises of ABT issuing 5 million new shares at subscription price of NOK 3.66 per share, equal to today's opening trading price of the Company's shares, with a 3-year lock up (the "Consideration Shares"). The cash component will in total be NOK 15 million, divided into two installments, depending on the Target Group's financial results. The first NOK 5 million is triggered by an EBT of NOK 6 million in the Target Group, the next NOK 10 million when the Target Group achieves an EBT of NOK 10 million. The Company's board of directors will convene at a later date to formally issue the Consideration Shares. The Transaction has been completed making ABT the 100 % direct and indirect owner of the Printprofil AS and Check Please AS (jointly with 3D, the "Target Group").New Risk • Aug 25New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended June 2023. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported June 2023 fiscal period end). Share price has been highly volatile over the past 3 months (11% average weekly change). Shareholders have been substantially diluted in the past year (209% increase in shares outstanding). Minor Risks Revenue is less than US$5m (kr14m revenue, or US$1.3m). Market cap is less than US$100m (kr245.0m market cap, or US$23.4m).New Risk • Jun 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Norwegian stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Shareholders have been substantially diluted in the past year (181% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Revenue is less than US$5m (kr14m revenue, or US$1.3m). Market cap is less than US$100m (kr227.8m market cap, or US$21.5m).お知らせ • Apr 28+ 3 more updatesAqua Bio Technology ASA to Report Q4, 2024 Results on Feb 12, 2025Aqua Bio Technology ASA announced that they will report Q4, 2024 results on Feb 12, 2025New Risk • Mar 11New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (24% average weekly change). Shareholders have been substantially diluted in the past year (183% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Revenue is less than US$5m (kr14m revenue, or US$1.3m). Market cap is less than US$100m (kr246.8m market cap, or US$23.7m).お知らせ • Feb 01Aqua Bio Technology ASA has filed a Follow-on Equity Offering in the amount of NOK 5 million.Aqua Bio Technology ASA has filed a Follow-on Equity Offering in the amount of NOK 5 million. Security Name: Shares Security Type: Common Stock Securities Offered: 1,000,000 Price\Range: NOK 5 Transaction Features: Rights Offeringお知らせ • Jan 30+ 1 more updateAqua Bio Technology ASA has filed a Follow-on Equity Offering in the amount of NOK 15 million.Aqua Bio Technology ASA has filed a Follow-on Equity Offering in the amount of NOK 15 million. Security Name: Shares Security Type: Common Stock Securities Offered: 3,000,000 Price\Range: NOK 5 Transaction Features: Subsequent Direct Listingお知らせ • Dec 21Aqua Bio Technology ASA (OB:ABTEC) entered into a share purchase agreement to acquire Cover Brands As from Medvind Holding As for NOK 16.5 million.Aqua Bio Technology ASA (OB:ABTEC) entered into a share purchase agreement to acquire Cover Brands As from Medvind Holding As for NOK 15.12 million on 19 December 2023. The purchase price will be settled through the Company issuing 6 million shares. Coverbrands revenue was above NOK 100 million.New Risk • Sep 15New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 129% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Shareholders have been substantially diluted in the past year (129% increase in shares outstanding). Minor Risks Revenue is less than US$5m (kr14m revenue, or US$1.3m). Market cap is less than US$100m (kr196.3m market cap, or US$18.3m).お知らせ • Sep 13Aqua Bio Technology Asa Receives European Patent for Use of Chaga in Cosmetic FormulationsAqua Bio Technology ASA (ABT) has been granted a European patent for use of Chaga in cosmetic formulations until 2037. This latest patent secures the rights in both US and Europe. The Chaga mushroom grows on birch trees throughout the northern hemisphere. The extract from Chagas mushroom has shown good results on wrinkles and general skin improvement. The extraction from Chagas mushroom can be beneficial for anyone suffering from skin conditions such as acne, allergic reactions, rashes, dermatitis, psoriasis, rosacea and eczema. The European and US patent secures ABT's use of this ingredient in existing and future cosmetic products and prohibits other players to use this ingredient without a specific license from ABT.New Risk • Aug 23New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 9.1% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Revenue is less than US$1m (kr7.2m revenue, or US$668k). Market cap is less than US$10m (kr78.7m market cap, or US$7.34m). Minor Risk Shareholders have been diluted in the past year (9.1% increase in shares outstanding).お知らせ • Jul 26Aqua Bio Technology ASA announced that it has received NOK 75.999999 million in fundingOn July 24, 2023, Aqua Bio Technology ASA closed the transaction. The company issued 25,333,333 common shares at an issue price of NOK 3 per share for gross proceeds of NOK 76,000,000. The transaction included participation from shareholders of Skinteam Norge AS and certain investors of the company.New Risk • Jul 26New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Norwegian stocks, typically moving 20% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Revenue is less than US$1m (kr7.2m revenue, or US$709k). Market cap is less than US$10m (kr99.2m market cap, or US$9.82m).お知らせ • Jul 25Aqua Bio Technology ASA announced that it expects to receive NOK 76 million in fundingAqua Bio Technology ASA announced a private placement for gross proceeds of NOK 76 million on July 24, 2023.お知らせ • Jul 24Aqua Bio Technology ASA (OB:ABTEC) entered into a binding agreement in principle to acquire SkinTeam Norge AS for NOK 45 million.Aqua Bio Technology ASA (OB:ABTEC) entered into a binding agreement in principle to acquire SkinTeam Norge AS for NOK 45 million on July 23, 2023. The purchase price will be used to subscribe for new shares in Aqua Bio Technology at a subscription price of NOK 3.お知らせ • Jan 21Aqua Bio Technology ASA Provides Earnings Guidance for the Full Year 2023Aqua Bio Technology ASA provided earnings guidance for the full year 2023. For the period, the company estimated gross income in 2023 for the company is approximately NOK 20-22 million with a gross margin of approximately between 65-70%.お知らせ • Dec 14+ 2 more updatesAqua Bio Technology ASA, Annual General Meeting, Apr 28, 2023Aqua Bio Technology ASA, Annual General Meeting, Apr 28, 2023.Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. No independent directors (5 non-independent directors). Director Roger Hofseth was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. No independent directors (5 non-independent directors). Director Roger Hofseth was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Recent Insider Transactions • Mar 10Chief Executive Officer recently bought kr55k worth of stockOn the 9th of March, Håvard Lindstrøm bought around 5k shares on-market at roughly kr10.97 per share. This was the largest purchase by an insider in the last 3 months. This was Håvard's only on-market trade for the last 12 months.Recent Insider Transactions • Jun 24Insider recently sold kr1.9m worth of stockOn the 23rd of June, Espen Dahl sold around 100k shares on-market at roughly kr19.49 per share. This was the largest sale by an insider in the last 3 months. Despite this recent sale, insiders have collectively bought kr55m more than they sold in the last 12 months.Recent Insider Transactions • Apr 21Director recently bought kr57m worth of stockOn the 20th of April, Roger Hofseth bought around 4m shares on-market at roughly kr12.72 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr58m more in shares than they have sold in the last 12 months.お知らせ • Mar 05Aqua Bio Technology ASA Announces Strategic Partnership with DCP DermoscienceAqua Bio Technology (ABT) has entered into a strategic partnership with the Canadian company DCP Dermoscience (DCP). The DCP agreement gave ABT exclusive rights to two new skin care series for development of its own brands and "private label" for ABT's customers. The first two skin care series following from the DCP agreement will be named "Seidr" and "Seidr Clinique". The name "Seidr" comes from Norse mythology and refers to supernatural abilities and powers practiced by strong women. The new brand "Seidr" is developed in close cooperation with the media bureau Glitch Studios. Both "Seidr" and "Seidr Clinique", like ABT's existing products, will contain high levels of active ingredients.お知らせ • Feb 26Aqua Bio Technology ASA Signs Exclusive Distribution Agreement with Moana Active Skincare Limited for New Zealand and AustraliaAqua Bio Technology ASA has signed an exclusive distribution agreement with Moana Active Skincare Limited for New Zealand and Australia. As informed in the stock exchange announcement on 10 September 2020, ABT retains its local presence and knowledge through the conclusion of an agreement with Moana Skincare New Zealand Limited. The duration of the agreement is three years.お知らせ • Feb 13Aqua Bio Technology ASA Signs an Distribution Agreement with Galaxa Pharma ApsAqua Bio Technology ASA has signed an distribution agreement with Galaxa Pharma Aps (Galaxa). The agreement grants Galaxa distribution rights for Denmark for the certified organic skincare line Moana Skincare. ABT has previously announced its acquisition of all rights to Moana Skincare. Galaxa has since 2014 been commercially active in Denmark as a representative of various foreign producers, with sales through drugstores (Matas), pharmacies and its own web shop.お知らせ • Feb 05Aqua Bio Technology ASA Signs Exclusive Distribution Agreement with Cosmed Beauty ASAqua Bio Technology ASA (ABT) has signed an exclusive distribution agreement with Cosmed Beauty AS (Cosmed). The agreement grants Cosmed exclusive distribution rights for Norway for the certified organic skincare line Moana Skincare. ABT has previously announced its acquisition of all rights to Moana Skincare. The initial term of the agreement is three years. Cosmed has shown continuous growth in the market and has established a distribution model that covers about approx. 900 stores.お知らせ • Jan 22+ 2 more updatesAqua Bio Technology ASA to Report Fiscal Year 2020 Results on Apr 14, 2021Aqua Bio Technology ASA announced that they will report fiscal year 2020 results on Apr 14, 2021Is New 90 Day High Low • Jan 21New 90-day high: kr9.20The company is up 79% from its price of kr5.15 on 23 October 2020. The Norwegian market is up 19% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 15% over the same period.分析記事 • Jan 20The Director of Aqua Bio Technology ASA (OB:ABT), Roger Hofseth, Just Bought A Few More SharesWhilst it may not be a huge deal, we thought it was good to see that the Aqua Bio Technology ASA ( OB:ABT ) Director...Recent Insider Transactions • Jan 20Director recently bought kr141k worth of stockOn the 18th of January, Roger Hofseth bought around 25k shares on-market at roughly kr5.64 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr1.2m more in shares than they have sold in the last 12 months.分析記事 • Dec 30Have Insiders Been Buying Aqua Bio Technology ASA (OB:ABT) Shares?It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...お知らせ • Dec 16Aqua Bio Technology ASA Announces Completion and Approval of Safety Studies of 6 Products from the Product Series Balance & VitalityAqua Bio Technology ASA announced that reference is made to the stock exchange announcement of 26 November 2020 regarding ongoing safety studies for the Nordic Beauty and Balance & Vitality product series. The company has received confirmation that the first 6 products from Balance & Vitality have passed the safety studies that the EU requires to be carried out before commercialization. The results for further 18 products are expected in January 2021, while the last 3 products are expected to be approved during first quarter 2021. Balance & Vitality will be a complete skincare series with products in all categories. The tests were performed at Eurofins. ABT expects the Balance & Vitality product series to be ready for distribution and sale in the first half of 2021.お知らせ • Dec 13Aqua Bio Technology Asa: Hydrafacial Has Entered into Partnership with Restorsea - Conversion Lab Launches Veritas Md PlatformAqua Bio Technology ASA has entered into partnership with Restorsea - Conversion Lab launches Veritas MD platform. As mentioned in the commercial update on November 26, 2020, Restorsea has recently entered into two license agreements with two partners in addition to the license agreement with NASDAQ-listed Conversion Labs. The positive trend from Restorsea's commercialization of ABT's proprietary technology increases the likelihood that ABT will receive additional renewal payment and increased revenue from the sale of ingredients and royalties from Restorsea and its licensees.お知らせ • Dec 12Aqua Bio Technology ASA (OB:ABT) completed the acquisition of distribution of Moana Skincare from Limited Liability Company Management Company AB GROUP.Aqua Bio Technology ASA (OB:ABT) has signed a letter of intent to acquire distribution of Moana Skincare from Limited Liability Company Management Company AB GROUP on August 2, 2019. Aqua Bio Technology ASA (OB:ABT) agreed to acquire the distribution of Moana Skincare from Limited Liability Company Management Company AB GROUP for NOK 32.5 million on September 10, 2020. Aqua Bio Technology ASA will pay consideration of NOK 26.7 million with three initial payment of NZD 0.5 million (NOK 3 million), second initial payment of NZD 0.25 million (NOK 1.5 million) and third initial payment of NZD 0.21 million (NOK 1.3 million) of NOK 5.8 million. The positive financial consequences of the acquisition will be significant in the event of successful revenue growth. Aqua Bio Technology ASA (OB:ABT) completed the acquisition of distribution of Moana Skincare from Limited Liability Company Management Company AB GROUP on December 10, 2020.お知らせ • Dec 11Aqua Bio Technology ASA Expects to Enter into Three-Year Agreement for the Distribution of Moana Products in New Zealand and AustraliaAqua Bio Technology ASA expected to enter into a three-year agreement for the distribution of Moana products in New Zealand and Australia. Moana Skincare currently consists of a portfolio of 19 skin care products, most of which are based on potent extracts from plants found in New Zealand's unspoiled nature. These have been used in traditional medicine by the country's indigenous people, the Maori, for centuries. The cornerstone of Moana Skincare's skin care products is a certified organic red seaweed found in the waters around New Zealand.お知らせ • Nov 28Aqua Bio Technology ASA Announces Completion and Approval of Safety Studies by Nordic BeautyAqua Bio Technology ASA announced that it received confirmation from Eurofins that Nordic Beauty has passed all the safety studies that the EU requires to be carried out before commercialization. The tests were performed at Eurofins. ABT expects the Nordic Beauty product series to be ready for distribution and sale in the first half of 2021.お知らせ • Sep 12Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 2.526 million.Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 2.526 million. Security Name: Shares Security Type: Common Stock Securities Offered: 505,200 Price\Range: NOK 5 Transaction Features: Rights Offering決済の安定と成長配当データの取得安定した配当: ABTECの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: ABTECの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Aqua Bio Technology 配当利回り対市場ABTEC 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (ABTEC)0%市場下位25% (NO)3.1%市場トップ25% (NO)7.1%業界平均 (Chemicals)3.4%アナリスト予想 (ABTEC) (最長3年)n/a注目すべき配当: ABTECは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: ABTECは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: ABTEC Norwegian市場において目立った配当金を支払っていません。株主配当金キャッシュフローカバレッジ: ABTECが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YNO 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/20 06:00終値2026/05/20 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Aqua Bio Technology ASA 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Tomas SkeivysNorne Securities AS
New Risk • May 13New major risk - Revenue sizeThe company makes less than US$1m in revenue. Total revenue: kr7.5m (US$822k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 62% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 6x increase in shares outstanding). Revenue is less than US$1m (kr7.5m revenue, or US$822k). Market cap is less than US$10m (kr79.4m market cap, or US$8.67m).
お知らせ • Mar 21Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 3.6824 million.Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 3.6824 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 388,240 Price\Range: NOK 5 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 348,240 Price\Range: NOK 5 Transaction Features: Rights Offering
お知らせ • Feb 13Aqua Bio Technology ASA has filed a Follow-on Equity Offering in the amount of NOK 4 million.Aqua Bio Technology ASA has filed a Follow-on Equity Offering in the amount of NOK 4 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 800,000 Price\Range: NOK 5 Transaction Features: Rights Offering
分析記事 • Jan 20Cautious Investors Not Rewarding Aqua Bio Technology ASA's (OB:ABTEC) Performance CompletelyYou may think that with a price-to-sales (or "P/S") ratio of 0.6x Aqua Bio Technology ASA ( OB:ABTEC ) is a stock worth...
New Risk • Dec 22New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 46% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr18m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 70% per year over the past 5 years. Shareholders have been substantially diluted in the past year (46% increase in shares outstanding). Market cap is less than US$10m (kr77.9m market cap, or US$7.69m).
New Risk • Dec 05New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 46% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr18m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 70% per year over the past 5 years. Shareholders have been substantially diluted in the past year (46% increase in shares outstanding). Market cap is less than US$10m (kr79.0m market cap, or US$7.81m).
Reported Earnings • Dec 01Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: kr6.88m (down 70% from 3Q 2024). Net loss: kr5.13m (loss narrowed 97% from 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 26 percentage points per year, which is a significant difference in performance.
New Risk • Dec 01New minor risk - Financial positionThe company has a high level of debt. Net debt to equity ratio: 1,462% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). High level of non-cash earnings (73% accrual ratio). Revenue is less than US$1m. Market cap is less than US$10m (kr53.3m market cap, or US$5.27m). Minor Risk High level of debt (1,462% net debt to equity).
お知らせ • Nov 22Aqua Bio Technology ASA, Annual General Meeting, May 22, 2026Aqua Bio Technology ASA, Annual General Meeting, May 22, 2026.
分析記事 • Nov 21Is Aqua Bio Technology (OB:ABTEC) A Risky Investment?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
お知らせ • Nov 21+ 3 more updatesAqua Bio Technology ASA to Report Q3, 2025 Results on Nov 26, 2025Aqua Bio Technology ASA announced that they will report Q3, 2025 results on Nov 26, 2025
分析記事 • Sep 24Aqua Bio Technology ASA (OB:ABTEC) Might Not Be As Mispriced As It Looks After Plunging 29%Aqua Bio Technology ASA ( OB:ABTEC ) shareholders that were waiting for something to happen have been dealt a blow with...
New Risk • Aug 31New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr32m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr32m free cash flow). Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings have declined by 73% per year over the past 5 years. Shareholders have been substantially diluted in the past year (57% increase in shares outstanding). Market cap is less than US$10m (kr85.9m market cap, or US$8.54m).
分析記事 • Aug 05Positive Sentiment Still Eludes Aqua Bio Technology ASA (OB:ABTEC) Following 27% Share Price SlumpOB:ABTEC 1 Year Share Price vs Fair Value Explore Aqua Bio Technology's Fair Values from the Community and select yours...
分析記事 • Jun 21Aqua Bio Technology ASA (OB:ABTEC) Stock's 54% Dive Might Signal An Opportunity But It Requires Some ScrutinyThe Aqua Bio Technology ASA ( OB:ABTEC ) share price has softened a substantial 54% over the previous 30 days, handing...
お知らせ • May 22Coc Invest AS, Cover Consult AS, Fiala Holding As, Hartmanns Norge As, Kø Consulting AS and Odp Holding As entered into an agreement to acquire 3D Innovation Nordic AS from Aqua Bio Technology ASA (OB:ABTEC).Coc Invest AS, Cover Consult AS, Fiala Holding As, Hartmanns Norge As, Kø Consulting AS and Odp Holding As entered into an agreement to acquire 3D Innovation Nordic AS from Aqua Bio Technology ASA (OB:ABTEC) on May 20, 2025. In separate transactions Aqua Bio Technology ASA (ABTEC) has entered into agreements with Coc Invest AS, Odp Holding AS, Fiala Holding AS, Kø Consulting AS, Cover Consult AS, and Hartmanns Norge AS for the sale of Ovalen AS, Cover Brands As. The combined consideration for Ovalen AS, 3D Innovation Nordic AS, and Coverbrands AS will be settled in 11 million Aqua Bio Technology shares and NOK 0.5 million in cash.
お知らせ • May 21Coc Invest AS, Odp Holding As, Fiala Holding As, Hartmanns Norge As, Kø Consulting AS and Cover Consult AS entered into an agreement to acquire Cover Brands As from Aqua Bio Technology ASA (OB:ABTEC).Coc Invest AS, Odp Holding As, Fiala Holding As, Hartmanns Norge As, Kø Consulting AS and Cover Consult AS entered into an agreement to acquire Cover Brands As from Aqua Bio Technology ASA (OB:ABTEC) on May 20, 2025. In separate transactions Aqua Bio Technology ASA (ABTEC) has entered into agreements with Coc Invest AS, Odp Holding AS, Fiala Holding AS, Kø Consulting AS, Cover Consult AS, and Hartmanns Norge AS for the sale of Ovalen AS, 3D Innovation Nordic AS. The combined consideration for Ovalen AS, 3D Innovation Nordic AS, and Coverbrands AS will be settled in 11 million Aqua Bio Technology shares and NOK 0.5 million in cash.
分析記事 • May 07Aqua Bio Technology ASA (OB:ABTEC) Stock Rockets 40% But Many Are Still Ignoring The CompanyThose holding Aqua Bio Technology ASA ( OB:ABTEC ) shares would be relieved that the share price has rebounded 40% in...
お知らせ • Apr 09Aqua Bio Technology Asa Announces Board ChangesAqua Bio Technology ASA at the extraordinary general meeting held on 9 April 2025, Roger Sedal is elected as new Chairman of the Board of Directors. Jan Pettersson shall resign from the Board of Directors. Following this, the Board of Directors shall consist of: Roger Sedal, Chairman; Lena Aas Varming, Director; Sofie Aimee Siem, Director; David Huggins, Director; Terje Blytt, Director; Jon Olav Ødegård, Observer.
お知らせ • Apr 04Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 2.055988 million.Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 2.055988 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 4,111,975 Price\Range: NOK 0.5 Transaction Features: Rights Offering
お知らせ • Mar 13Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 24.216 million.Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 24.216 million. Security Name: Shares Security Type: Common Stock Securities Offered: 48,432,000 Price\Range: NOK 0.5 Transaction Features: Subsequent Direct Listing
New Risk • Mar 11New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: kr80.1m (US$7.43m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (31% average weekly change). High level of non-cash earnings (41% accrual ratio). Shareholders have been substantially diluted in the past year (86% increase in shares outstanding). Market cap is less than US$10m (kr80.1m market cap, or US$7.43m).
お知らせ • Feb 26+ 2 more updatesAqua Bio Technology ASA, Annual General Meeting, Jun 25, 2025Aqua Bio Technology ASA, Annual General Meeting, Jun 25, 2025.
お知らせ • Feb 12Aqua Bio Technology ASA Provides Earnings Guidance for the Fiscal Year 2025Aqua Bio Technology ASA provided earnings guidance for the fiscal year 2025. For the period, consolidated revenue is expected to exceed NOK 500.0 million applying Norwegian Generally Accepted Accounting Principles (N-GAAP), indicating conservative revenue growth compared to pro forma revenue (based on N-GAAP) assuming all 2024 acquisitions were completed as of January 1, 2024.
お知らせ • Jan 21Aqua Bio Technology Announces Resignation of Celine Maria Sedal from Board of DirectorsAqua Bio Technology ASA has been informed that Board member Celine Maria Sedal has chosen to resign from the Company's Board of Directors with immediate effect. The resignation is due to Sedal not being able to hold the position as member of the Board of Directors in her newly assumed employment.
New Risk • Dec 30New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (22% average weekly change). High level of non-cash earnings (41% accrual ratio). Shareholders have been substantially diluted in the past year (97% increase in shares outstanding). Minor Risk Market cap is less than US$100m (kr234.0m market cap, or US$20.6m).
New Risk • Nov 22New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 130% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Shareholders have been substantially diluted in the past year (130% increase in shares outstanding). Minor Risks Revenue is less than US$5m (kr14m revenue, or US$1.2m). Market cap is less than US$100m (kr217.7m market cap, or US$19.6m).
New Risk • Nov 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Norwegian stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Shareholders have been diluted in the past year (47% increase in shares outstanding). Revenue is less than US$5m (kr14m revenue, or US$1.2m). Market cap is less than US$100m (kr191.1m market cap, or US$17.3m).
お知らせ • Oct 22Aqua Bio Technology ASA Announces CEO Changes, Effective December 1, 2024Aqua Bio Technology ASA announced that Fredrik W. Henriksen has been appointed Chief Executive Officer of the Company. Mr. Henriksen assumes his position on 1 December 2024, and replaces Håvard Lindstrøm, who has served as CEO for more than 3 years. Mr. Henriksen has since 2016 served as Commercial Director in Norengros. He has also 15 years in different start-ups prior to working within the sales and distribution industry. Håvard Lindstrøm started as CEO in 2021.
お知らせ • Aug 29Aqua Bio Technology ASA (OB:ABTEC) completed the acquisition of 3d Innovation Nordic As from Coc Invest AS.Aqua Bio Technology ASA (OB:ABTEC) entered into an agreement to acquire 3d Innovation Nordic As from Coc Invest AS on April 25, 2024. Pursuant to the Agreement, Aqua Bio Technology also agreed to acquire Printprofil AS and Check Please AS from Coc Invest AS. The combined consideration for both the transactions is NOK 40.4 million. Under the Agreement, the purchase price for the Acquisitions shall be settled in a combination of shares and cash, subject to certain conditions. NOK 5 million shares in ABT will be issued at a price of NOK 6 per share, with a 3-year lock up. The cash will be total NOK 15 million, divided into two installments, depending on the Target Group's (collectively Printprofil AS and Check Please AS (jointly with 3D Innovation) financial results. The first NOK 5 million is triggered by an EBT of NOK 6 million in the Target Group, the next NOK 10 million when the Target Group achieves an EBT of NOK 10 million. As of 2023, 3d Innovation, Printprofil AS and Check Please had reported a EBIDTA of NOK 5 million and turnover of NOK 87.6 million, of which 3d Innovation had a turnover of NOK 73 million. The completion of the Acquisitions is subject to satisfactory due diligence and approval from ABT's board of directors. Aqua Bio Technology ASA (OB:ABTEC) completed the acquisition of 3d Innovation Nordic As from Coc Invest AS on August 28, 2024. The purchase price for the Transaction shall be settled in a combination of shares and cash, subject to certain conditions. The share component comprises of ABT issuing 5 million new shares at subscription price of NOK 3.66 per share, equal to today's opening trading price of the Company's shares, with a 3-year lock up (the "Consideration Shares"). The cash component will in total be NOK 15 million, divided into two installments, depending on the Target Group's financial results. The first NOK 5 million is triggered by an EBT of NOK 6 million in the Target Group, the next NOK 10 million when the Target Group achieves an EBT of NOK 10 million. The Company's board of directors will convene at a later date to formally issue the Consideration Shares. The Transaction has been completed making ABT the 100 % direct and indirect owner of the Printprofil AS and Check Please AS (jointly with 3D, the "Target Group").
New Risk • Aug 25New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended June 2023. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported June 2023 fiscal period end). Share price has been highly volatile over the past 3 months (11% average weekly change). Shareholders have been substantially diluted in the past year (209% increase in shares outstanding). Minor Risks Revenue is less than US$5m (kr14m revenue, or US$1.3m). Market cap is less than US$100m (kr245.0m market cap, or US$23.4m).
New Risk • Jun 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Norwegian stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Shareholders have been substantially diluted in the past year (181% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Revenue is less than US$5m (kr14m revenue, or US$1.3m). Market cap is less than US$100m (kr227.8m market cap, or US$21.5m).
お知らせ • Apr 28+ 3 more updatesAqua Bio Technology ASA to Report Q4, 2024 Results on Feb 12, 2025Aqua Bio Technology ASA announced that they will report Q4, 2024 results on Feb 12, 2025
New Risk • Mar 11New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (24% average weekly change). Shareholders have been substantially diluted in the past year (183% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Revenue is less than US$5m (kr14m revenue, or US$1.3m). Market cap is less than US$100m (kr246.8m market cap, or US$23.7m).
お知らせ • Feb 01Aqua Bio Technology ASA has filed a Follow-on Equity Offering in the amount of NOK 5 million.Aqua Bio Technology ASA has filed a Follow-on Equity Offering in the amount of NOK 5 million. Security Name: Shares Security Type: Common Stock Securities Offered: 1,000,000 Price\Range: NOK 5 Transaction Features: Rights Offering
お知らせ • Jan 30+ 1 more updateAqua Bio Technology ASA has filed a Follow-on Equity Offering in the amount of NOK 15 million.Aqua Bio Technology ASA has filed a Follow-on Equity Offering in the amount of NOK 15 million. Security Name: Shares Security Type: Common Stock Securities Offered: 3,000,000 Price\Range: NOK 5 Transaction Features: Subsequent Direct Listing
お知らせ • Dec 21Aqua Bio Technology ASA (OB:ABTEC) entered into a share purchase agreement to acquire Cover Brands As from Medvind Holding As for NOK 16.5 million.Aqua Bio Technology ASA (OB:ABTEC) entered into a share purchase agreement to acquire Cover Brands As from Medvind Holding As for NOK 15.12 million on 19 December 2023. The purchase price will be settled through the Company issuing 6 million shares. Coverbrands revenue was above NOK 100 million.
New Risk • Sep 15New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 129% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Shareholders have been substantially diluted in the past year (129% increase in shares outstanding). Minor Risks Revenue is less than US$5m (kr14m revenue, or US$1.3m). Market cap is less than US$100m (kr196.3m market cap, or US$18.3m).
お知らせ • Sep 13Aqua Bio Technology Asa Receives European Patent for Use of Chaga in Cosmetic FormulationsAqua Bio Technology ASA (ABT) has been granted a European patent for use of Chaga in cosmetic formulations until 2037. This latest patent secures the rights in both US and Europe. The Chaga mushroom grows on birch trees throughout the northern hemisphere. The extract from Chagas mushroom has shown good results on wrinkles and general skin improvement. The extraction from Chagas mushroom can be beneficial for anyone suffering from skin conditions such as acne, allergic reactions, rashes, dermatitis, psoriasis, rosacea and eczema. The European and US patent secures ABT's use of this ingredient in existing and future cosmetic products and prohibits other players to use this ingredient without a specific license from ABT.
New Risk • Aug 23New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 9.1% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Revenue is less than US$1m (kr7.2m revenue, or US$668k). Market cap is less than US$10m (kr78.7m market cap, or US$7.34m). Minor Risk Shareholders have been diluted in the past year (9.1% increase in shares outstanding).
お知らせ • Jul 26Aqua Bio Technology ASA announced that it has received NOK 75.999999 million in fundingOn July 24, 2023, Aqua Bio Technology ASA closed the transaction. The company issued 25,333,333 common shares at an issue price of NOK 3 per share for gross proceeds of NOK 76,000,000. The transaction included participation from shareholders of Skinteam Norge AS and certain investors of the company.
New Risk • Jul 26New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Norwegian stocks, typically moving 20% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Revenue is less than US$1m (kr7.2m revenue, or US$709k). Market cap is less than US$10m (kr99.2m market cap, or US$9.82m).
お知らせ • Jul 25Aqua Bio Technology ASA announced that it expects to receive NOK 76 million in fundingAqua Bio Technology ASA announced a private placement for gross proceeds of NOK 76 million on July 24, 2023.
お知らせ • Jul 24Aqua Bio Technology ASA (OB:ABTEC) entered into a binding agreement in principle to acquire SkinTeam Norge AS for NOK 45 million.Aqua Bio Technology ASA (OB:ABTEC) entered into a binding agreement in principle to acquire SkinTeam Norge AS for NOK 45 million on July 23, 2023. The purchase price will be used to subscribe for new shares in Aqua Bio Technology at a subscription price of NOK 3.
お知らせ • Jan 21Aqua Bio Technology ASA Provides Earnings Guidance for the Full Year 2023Aqua Bio Technology ASA provided earnings guidance for the full year 2023. For the period, the company estimated gross income in 2023 for the company is approximately NOK 20-22 million with a gross margin of approximately between 65-70%.
お知らせ • Dec 14+ 2 more updatesAqua Bio Technology ASA, Annual General Meeting, Apr 28, 2023Aqua Bio Technology ASA, Annual General Meeting, Apr 28, 2023.
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. No independent directors (5 non-independent directors). Director Roger Hofseth was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. No independent directors (5 non-independent directors). Director Roger Hofseth was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Recent Insider Transactions • Mar 10Chief Executive Officer recently bought kr55k worth of stockOn the 9th of March, Håvard Lindstrøm bought around 5k shares on-market at roughly kr10.97 per share. This was the largest purchase by an insider in the last 3 months. This was Håvard's only on-market trade for the last 12 months.
Recent Insider Transactions • Jun 24Insider recently sold kr1.9m worth of stockOn the 23rd of June, Espen Dahl sold around 100k shares on-market at roughly kr19.49 per share. This was the largest sale by an insider in the last 3 months. Despite this recent sale, insiders have collectively bought kr55m more than they sold in the last 12 months.
Recent Insider Transactions • Apr 21Director recently bought kr57m worth of stockOn the 20th of April, Roger Hofseth bought around 4m shares on-market at roughly kr12.72 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr58m more in shares than they have sold in the last 12 months.
お知らせ • Mar 05Aqua Bio Technology ASA Announces Strategic Partnership with DCP DermoscienceAqua Bio Technology (ABT) has entered into a strategic partnership with the Canadian company DCP Dermoscience (DCP). The DCP agreement gave ABT exclusive rights to two new skin care series for development of its own brands and "private label" for ABT's customers. The first two skin care series following from the DCP agreement will be named "Seidr" and "Seidr Clinique". The name "Seidr" comes from Norse mythology and refers to supernatural abilities and powers practiced by strong women. The new brand "Seidr" is developed in close cooperation with the media bureau Glitch Studios. Both "Seidr" and "Seidr Clinique", like ABT's existing products, will contain high levels of active ingredients.
お知らせ • Feb 26Aqua Bio Technology ASA Signs Exclusive Distribution Agreement with Moana Active Skincare Limited for New Zealand and AustraliaAqua Bio Technology ASA has signed an exclusive distribution agreement with Moana Active Skincare Limited for New Zealand and Australia. As informed in the stock exchange announcement on 10 September 2020, ABT retains its local presence and knowledge through the conclusion of an agreement with Moana Skincare New Zealand Limited. The duration of the agreement is three years.
お知らせ • Feb 13Aqua Bio Technology ASA Signs an Distribution Agreement with Galaxa Pharma ApsAqua Bio Technology ASA has signed an distribution agreement with Galaxa Pharma Aps (Galaxa). The agreement grants Galaxa distribution rights for Denmark for the certified organic skincare line Moana Skincare. ABT has previously announced its acquisition of all rights to Moana Skincare. Galaxa has since 2014 been commercially active in Denmark as a representative of various foreign producers, with sales through drugstores (Matas), pharmacies and its own web shop.
お知らせ • Feb 05Aqua Bio Technology ASA Signs Exclusive Distribution Agreement with Cosmed Beauty ASAqua Bio Technology ASA (ABT) has signed an exclusive distribution agreement with Cosmed Beauty AS (Cosmed). The agreement grants Cosmed exclusive distribution rights for Norway for the certified organic skincare line Moana Skincare. ABT has previously announced its acquisition of all rights to Moana Skincare. The initial term of the agreement is three years. Cosmed has shown continuous growth in the market and has established a distribution model that covers about approx. 900 stores.
お知らせ • Jan 22+ 2 more updatesAqua Bio Technology ASA to Report Fiscal Year 2020 Results on Apr 14, 2021Aqua Bio Technology ASA announced that they will report fiscal year 2020 results on Apr 14, 2021
Is New 90 Day High Low • Jan 21New 90-day high: kr9.20The company is up 79% from its price of kr5.15 on 23 October 2020. The Norwegian market is up 19% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 15% over the same period.
分析記事 • Jan 20The Director of Aqua Bio Technology ASA (OB:ABT), Roger Hofseth, Just Bought A Few More SharesWhilst it may not be a huge deal, we thought it was good to see that the Aqua Bio Technology ASA ( OB:ABT ) Director...
Recent Insider Transactions • Jan 20Director recently bought kr141k worth of stockOn the 18th of January, Roger Hofseth bought around 25k shares on-market at roughly kr5.64 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr1.2m more in shares than they have sold in the last 12 months.
分析記事 • Dec 30Have Insiders Been Buying Aqua Bio Technology ASA (OB:ABT) Shares?It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...
お知らせ • Dec 16Aqua Bio Technology ASA Announces Completion and Approval of Safety Studies of 6 Products from the Product Series Balance & VitalityAqua Bio Technology ASA announced that reference is made to the stock exchange announcement of 26 November 2020 regarding ongoing safety studies for the Nordic Beauty and Balance & Vitality product series. The company has received confirmation that the first 6 products from Balance & Vitality have passed the safety studies that the EU requires to be carried out before commercialization. The results for further 18 products are expected in January 2021, while the last 3 products are expected to be approved during first quarter 2021. Balance & Vitality will be a complete skincare series with products in all categories. The tests were performed at Eurofins. ABT expects the Balance & Vitality product series to be ready for distribution and sale in the first half of 2021.
お知らせ • Dec 13Aqua Bio Technology Asa: Hydrafacial Has Entered into Partnership with Restorsea - Conversion Lab Launches Veritas Md PlatformAqua Bio Technology ASA has entered into partnership with Restorsea - Conversion Lab launches Veritas MD platform. As mentioned in the commercial update on November 26, 2020, Restorsea has recently entered into two license agreements with two partners in addition to the license agreement with NASDAQ-listed Conversion Labs. The positive trend from Restorsea's commercialization of ABT's proprietary technology increases the likelihood that ABT will receive additional renewal payment and increased revenue from the sale of ingredients and royalties from Restorsea and its licensees.
お知らせ • Dec 12Aqua Bio Technology ASA (OB:ABT) completed the acquisition of distribution of Moana Skincare from Limited Liability Company Management Company AB GROUP.Aqua Bio Technology ASA (OB:ABT) has signed a letter of intent to acquire distribution of Moana Skincare from Limited Liability Company Management Company AB GROUP on August 2, 2019. Aqua Bio Technology ASA (OB:ABT) agreed to acquire the distribution of Moana Skincare from Limited Liability Company Management Company AB GROUP for NOK 32.5 million on September 10, 2020. Aqua Bio Technology ASA will pay consideration of NOK 26.7 million with three initial payment of NZD 0.5 million (NOK 3 million), second initial payment of NZD 0.25 million (NOK 1.5 million) and third initial payment of NZD 0.21 million (NOK 1.3 million) of NOK 5.8 million. The positive financial consequences of the acquisition will be significant in the event of successful revenue growth. Aqua Bio Technology ASA (OB:ABT) completed the acquisition of distribution of Moana Skincare from Limited Liability Company Management Company AB GROUP on December 10, 2020.
お知らせ • Dec 11Aqua Bio Technology ASA Expects to Enter into Three-Year Agreement for the Distribution of Moana Products in New Zealand and AustraliaAqua Bio Technology ASA expected to enter into a three-year agreement for the distribution of Moana products in New Zealand and Australia. Moana Skincare currently consists of a portfolio of 19 skin care products, most of which are based on potent extracts from plants found in New Zealand's unspoiled nature. These have been used in traditional medicine by the country's indigenous people, the Maori, for centuries. The cornerstone of Moana Skincare's skin care products is a certified organic red seaweed found in the waters around New Zealand.
お知らせ • Nov 28Aqua Bio Technology ASA Announces Completion and Approval of Safety Studies by Nordic BeautyAqua Bio Technology ASA announced that it received confirmation from Eurofins that Nordic Beauty has passed all the safety studies that the EU requires to be carried out before commercialization. The tests were performed at Eurofins. ABT expects the Nordic Beauty product series to be ready for distribution and sale in the first half of 2021.
お知らせ • Sep 12Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 2.526 million.Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 2.526 million. Security Name: Shares Security Type: Common Stock Securities Offered: 505,200 Price\Range: NOK 5 Transaction Features: Rights Offering